- In August 2023, Lumenis received FDA clearance for its PiQo4 picosecond laser, a state-of-the-art device designed for tattoo removal, pigmentation treatment, and wrinkle reduction. This regulatory approval underscores the growing advancements in non-invasive aesthetic treatments, providing precise and highly effective solutions for various dermatological concerns. The approval of the PiQo4 laser is particularly relevant to the global dermatology treatment devices market, as it reflects the increasing demand for advanced technologies that offer enhanced treatment outcomes with minimal patient downtime
- In July 2023, Canfield Scientific unveiled its latest dermatology innovations at the 25th World Congress of Dermatology held in Singapore from July 4th to 7th. The showcased products included IntelliStudio, VEOS, DermaGraphix, and VECTRA WB360, which highlight the company’s commitment to advancing imaging and diagnostic technologies designed to improve clinical outcomes in dermatological practices. These innovations are highly relevant to the global dermatology treatment devices market, as they reflect the increasing emphasis on precision diagnostics and personalized treatment solutions
- In April 2023, Canfield Scientific attained ISO 9001:2015 and ISO 13485:2016 certifications for its quality management systems. This dual certification emphasizes Canfield's ongoing dedication to upholding rigorous standards in product quality and regulatory compliance for its medical imaging and software solutions within the dermatology sector. The achievement of these certifications is highly significant for the global dermatology treatment devices market, as it reflects the increasing importance of quality assurance and regulatory adherence in the development of advanced dermatology technologies
- In February 2023, Candela Corporation received Health Canada’s licensing for its dual-wavelength Frax Pro non-ablative fractional laser platform and the Nordlys multi-application platform. These advanced technologies, which integrate Selective Waveband Technology (SWT), are designed to broaden treatment options in medical aesthetics, providing versatile solutions for a variety of skin conditions while enhancing safety and efficacy. This regulatory approval is highly relevant to the global dermatology treatment devices market, as it reflects the increasing demand for innovative, non-invasive treatments that offer customizable, effective solutions for a range of dermatological concerns
- In February 2023, Candela Corporation, a global leader in medical aesthetic devices, announced that its dual-wavelength Frax Pro non-ablative fractional laser platform and the Nordlys multi-application platform, featuring Selective Waveband Technology (SWT), were granted licensing by Health Canada and are now available for use. The availability of these innovative platforms in the global dermatology treatment devices market highlights the ongoing shift towards non-invasive aesthetic solutions that provide customizable and effective treatments for diverse dermatological concerns
